Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

Bril F, McPhaul MJ, Caulfield MP, Castille JM, Poynard T, Soldevila-Pico C, Clark VC, Firpi-Morell RJ, Lai J, Cusi K.

J Investig Med. 2018 Oct 10. pii: jim-2018-000864. doi: 10.1136/jim-2018-000864. [Epub ahead of print]

PMID:
30309884
2.

Comparability of Lipoprotein Particle Number Concentrations Across ES-DMA, NMR, LC-MS/MS, Immunonephelometry, and VAP: In Search of a Candidate Reference Measurement Procedure for apoB and non-HDL-P Standardization.

Delatour V, Clouet-Foraison N, Gaie-Levrel F, Marcovina SM, Hoofnagle AN, Kuklenyik Z, Caulfield MP, Otvos JD, Krauss RM, Kulkarni KR, Contois JH, Remaley AT, Vesper HW, Cobbaert CM, Gillery P.

Clin Chem. 2018 Oct;64(10):1485-1495. doi: 10.1373/clinchem.2018.288746. Epub 2018 Aug 7.

PMID:
30087138
3.

Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Bril F, Millán L, Kalavalapalli S, McPhaul MJ, Caulfield MP, Martinez-Arranz I, Alonso C, Ortiz Betes P, Mato JM, Cusi K.

Diabetes Obes Metab. 2018 Jul;20(7):1702-1709. doi: 10.1111/dom.13285. Epub 2018 Apr 14.

PMID:
29527789
4.

LDL subfractions are associated with incident cardiovascular disease in the Malmö Prevention Project Study.

Shiffman D, Louie JZ, Caulfield MP, Nilsson PM, Devlin JJ, Melander O.

Atherosclerosis. 2017 Aug;263:287-292. doi: 10.1016/j.atherosclerosis.2017.07.003. Epub 2017 Jul 5.

5.

Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis.

Shiffman D, Arellano AR, Caulfield MP, Louie JZ, Bare LA, Devlin JJ, Melander O.

BMC Cardiovasc Disord. 2016 Dec 7;16(1):251.

6.

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.

Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, Glynn RJ, Ridker PM, Krauss RM.

Circulation. 2015 Dec 8;132(23):2220-9. doi: 10.1161/CIRCULATIONAHA.115.016857. Epub 2015 Sep 25.

7.

Low-Density Lipoprotein Particle Number Is Associated With Cardiovascular Events Among Those Not Classified Into Statin Benefit Groups.

Melander O, Shiffman D, Caulfield MP, Louie JZ, Rowland CM, Devlin JJ, Krauss RM.

J Am Coll Cardiol. 2015 Jun 16;65(23):2571-3. doi: 10.1016/j.jacc.2015.02.077. No abstract available.

8.

Relationship between insulin resistance and amino acids in women and men.

Seibert R, Abbasi F, Hantash FM, Caulfield MP, Reaven G, Kim SH.

Physiol Rep. 2015 May;3(5). pii: e12392. doi: 10.14814/phy2.12392.

9.

Low circulating 25-hydroxyvitamin D concentrations are associated with defects in insulin action and insulin secretion in persons with prediabetes.

Abbasi F, Blasey C, Feldman D, Caulfield MP, Hantash FM, Reaven GM.

J Nutr. 2015 Apr;145(4):714-9. doi: 10.3945/jn.114.209171. Epub 2015 Mar 4.

10.

Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: a prospective cohort study.

Landenhed M, Engström G, Gottsäter A, Caulfield MP, Hedblad B, Newton-Cheh C, Melander O, Smith JG.

J Am Heart Assoc. 2015 Jan 21;4(1):e001513. doi: 10.1161/JAHA.114.001513.

11.

A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.

Canas JA, Ross JL, Taboada MV, Sikes KM, Damaso LC, Hossain J, Caulfield MP, Gidding SS, Mauras N.

Pediatr Diabetes. 2015 Mar;16(2):79-89. doi: 10.1111/pedi.12245. Epub 2014 Nov 22.

PMID:
25418907
12.

Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)".

Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S.

Circulation. 2014 Oct 21;130(17):e152. doi: 10.1161/CIRCULATIONAHA.114.010927. No abstract available.

PMID:
25332285
13.

Relationship among 25-hydroxyvitamin D concentrations, insulin action, and cardiovascular disease risk in patients with essential hypertension.

Abbasi F, Feldman D, Caulfield MP, Hantash FM, Reaven GM.

Am J Hypertens. 2015 Feb;28(2):266-72. doi: 10.1093/ajh/hpu136. Epub 2014 Aug 19.

14.

The measurement of 3-epimer 25-hydroxyvitamin D by mass spectrometry in clinical specimens detects inconsequential levels in adult subjects.

Goldman MM, Viec KV, Caulfield MP, Reitz RE, McPhaul MJ, Clarke NJ.

J Investig Med. 2014 Apr;62(4):690-5. doi: 10.2310/JIM.0000000000000067.

PMID:
24583901
15.

Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S.

Circulation. 2014 Feb 11;129(6):635-42. doi: 10.1161/CIRCULATIONAHA.113.004406. Epub 2013 Nov 17.

16.

Heat stress: a major contributor to poor animal welfare associated with long-haul live export voyages.

Caulfield MP, Cambridge H, Foster SF, McGreevy PD.

Vet J. 2014 Feb;199(2):223-8. doi: 10.1016/j.tvjl.2013.09.018. Epub 2013 Sep 21.

17.

Classification of LDL phenotypes by 4 methods of determining lipoprotein particle size.

Sninsky JJ, Rowland CM, Baca AM, Caulfield MP, Superko HR.

J Investig Med. 2013 Aug;61(6):942-9. doi: 10.2310/JIM.0b013e31829d9d17.

PMID:
23838699
18.

Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory.

Chen Z, Caulfield MP, McPhaul MJ, Reitz RE, Taylor SW, Clarke NJ.

Clin Chem. 2013 Sep;59(9):1349-56. doi: 10.1373/clinchem.2012.199794. Epub 2013 May 24.

19.

Bile acid concentration reference ranges in a pregnant Latina population.

Lee RH, Ouzounian JG, Goodwin TM, Incerpi MH, Miller DA, Zhang K, Caulfield MP, Reitz R, Stanczyk FZ.

Am J Perinatol. 2013 May;30(5):389-93. doi: 10.1055/s-0032-1326982. Epub 2012 Nov 16.

PMID:
23161351
20.

Lipoprotein subfractions by ion mobility in lean and obese children.

Benson M, Hossain J, Caulfield MP, Damaso L, Gidding S, Mauras N.

J Pediatr. 2012 Dec;161(6):997-1003. doi: 10.1016/j.jpeds.2012.05.060. Epub 2012 Jul 20.

PMID:
22819275
21.

Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients.

Noori N, Caulfield MP, Salameh WA, Reitz RE, Nicholas SB, Molnar MZ, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K.

Clin J Am Soc Nephrol. 2011 Dec;6(12):2861-70. doi: 10.2215/CJN.03650411. Epub 2011 Oct 27.

22.

Testosterone reference ranges in normally cycling healthy premenopausal women.

Braunstein GD, Reitz RE, Buch A, Schnell D, Caulfield MP.

J Sex Med. 2011 Oct;8(10):2924-34. doi: 10.1111/j.1743-6109.2011.02380.x. Epub 2011 Jul 19.

PMID:
21771278
23.

Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: total and free testosterone reference ranges.

Salameh WA, Redor-Goldman MM, Clarke NJ, Reitz RE, Caulfield MP.

Steroids. 2010 Feb;75(2):169-75. doi: 10.1016/j.steroids.2009.11.004. Epub 2009 Nov 17.

PMID:
19925815
24.

Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk.

Musunuru K, Orho-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, Berglund G, Hedblad B, Engström G, Williams PT, Kathiresan S, Melander O, Krauss RM.

Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1975-80. doi: 10.1161/ATVBAHA.109.190405. Epub 2009 Sep 3.

25.

The questionable value of some science-based 'welfare' assessments in intensive animal farming: sow stalls as an illustrative example.

Caulfield MP, Cambridge H.

Aust Vet J. 2008 Nov;86(11):446-8. doi: 10.1111/j.1751-0813.2008.00338.x.

PMID:
18959536
26.

Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis.

Caulfield MP, Li S, Lee G, Blanche PJ, Salameh WA, Benner WH, Reitz RE, Krauss RM.

Clin Chem. 2008 Aug;54(8):1307-16. doi: 10.1373/clinchem.2007.100586. Epub 2008 May 29.

27.

A cross-sectional study of bone turnover markers in healthy premenopausal women.

de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, Rosenberg E, Reitz RE.

Bone. 2007 May;40(5):1222-30. Epub 2007 Jan 24.

PMID:
17331821
28.

Biochemical markers of bone turnover and their utility in osteoporosis.

Caulfield MP, Reitz RE.

MLO Med Lab Obs. 2004 Apr;36(4):34-7. No abstract available.

PMID:
15119056
29.

The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens.

Caulfield MP, Lynn T, Gottschalk ME, Jones KL, Taylor NF, Malunowicz EM, Shackleton CH, Reitz RE, Fisher DA.

J Clin Endocrinol Metab. 2002 Aug;87(8):3682-90.

PMID:
12161496
30.

Use of antisense expression plasmids to attenuate G-protein expression in primary neurons.

Buckley NJ, Abogadie FC, Brown DA, Dayrell M, Caulfield MP, Delmas P, Haley JE.

Methods Enzymol. 2000;314:136-48. No abstract available.

PMID:
10565010
32.

Selective activation of heterologously expressed G protein-gated K+ channels by M2 muscarinic receptors in rat sympathetic neurones.

Fernandez-Fernandez JM, Wanaverbecq N, Halley P, Caulfield MP, Brown DA.

J Physiol. 1999 Mar 15;515 ( Pt 3):631-7.

33.

G-proteins and G-protein subunits mediating cholinergic inhibition of N-type calcium currents in sympathetic neurons.

Delmas P, Abogadie FC, Dayrell M, Haley JE, Milligan G, Caulfield MP, Brown DA, Buckley NJ.

Eur J Neurosci. 1998 May;10(5):1654-66.

PMID:
9751138
34.

International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

Caulfield MP, Birdsall NJ.

Pharmacol Rev. 1998 Jun;50(2):279-90. Review. No abstract available.

35.

The alpha subunit of Gq contributes to muscarinic inhibition of the M-type potassium current in sympathetic neurons.

Haley JE, Abogadie FC, Delmas P, Dayrell M, Vallis Y, Milligan G, Caulfield MP, Brown DA, Buckley NJ.

J Neurosci. 1998 Jun 15;18(12):4521-31.

36.

On the role of endogenous G-protein beta gamma subunits in N-type Ca2+ current inhibition by neurotransmitters in rat sympathetic neurones.

Delmas P, Brown DA, Dayrell M, Abogadie FC, Caulfield MP, Buckley NJ.

J Physiol. 1998 Jan 15;506 ( Pt 2):319-29.

37.

Design, synthesis and utility of novel benzophenone-containing calcitonin analogs for photoaffinity labeling the calcitonin receptor.

Suva LJ, Flannery MS, Caulfield MP, Findlay DM, Jüppner H, Goldring SR, Rosenblatt M, Chorev M.

J Pharmacol Exp Ther. 1997 Nov;283(2):876-84.

38.

Use of antisense-generating plasmids to probe the function of signal transduction proteins in primary neurons.

Abogadie FC, Vallis Y, Buckley NJ, Caulfield MP.

Methods Mol Biol. 1997;83:217-25. Review. No abstract available.

PMID:
9210148
39.

Muscarinic mechanisms in nerve cells.

Brown DA, Abogadie FC, Allen TG, Buckley NJ, Caulfield MP, Delmas P, Haley JE, Lamas JA, Selyanko AA.

Life Sci. 1997;60(13-14):1137-44. Review.

PMID:
9121358
40.
41.

Bradykinin excites rat sympathetic neurons by inhibition of M current through a mechanism involving B2 receptors and G alpha q/11.

Jones S, Brown DA, Milligan G, Willer E, Buckley NJ, Caulfield MP.

Neuron. 1995 Feb;14(2):399-405.

42.

Muscarinic M-current inhibition via G alpha q/11 and alpha-adrenoceptor inhibition of Ca2+ current via G alpha o in rat sympathetic neurones.

Caulfield MP, Jones S, Vallis Y, Buckley NJ, Kim GD, Milligan G, Brown DA.

J Physiol. 1994 Jun 15;477 ( Pt 3):415-22.

43.

Inactivation by plasma may be responsible for lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy.

Kukreja SC, D'Anza JJ, Wimbiscus SA, Fisher JE, McKee RL, Caulfield MP, Rosenblatt M.

Endocrinology. 1994 May;134(5):2184-8.

PMID:
8156920
44.

Injection of antisera into cells to study G-protein regulation of channel function.

McFadzean I, Caulfield MP, Vallis Y, Brown DA.

Methods Enzymol. 1994;238:357-64. No abstract available.

PMID:
7528321
45.

Receptor subtypes or species homologues: relevance to drug discovery.

Hall JM, Caulfield MP, Watson SP, Guard S.

Trends Pharmacol Sci. 1993 Oct;14(10):376-83. Review.

PMID:
8296394
46.

Circular dichroism (CD) studies of antagonists derived from parathyroid hormone-related protein.

Chorev M, Epand RF, Rosenblatt M, Caulfield MP, Epand RM.

Int J Pept Protein Res. 1993 Oct;42(4):342-5.

PMID:
8244629
47.

Muscarinic receptors--characterization, coupling and function.

Caulfield MP.

Pharmacol Ther. 1993 Jun;58(3):319-79. Review.

PMID:
7504306
48.

Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.

Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M.

Endocrinology. 1993 Mar;132(3):1411-3.

PMID:
8440195
49.

Postsynaptic actions of acetylcholine: the coupling of muscarinic receptor subtypes to neuronal ion channels.

Caulfield MP, Robbins J, Higashida H, Brown DA.

Prog Brain Res. 1993;98:293-301. Review. No abstract available.

PMID:
7504311

Supplemental Content

Loading ...
Support Center